Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Clinical trial NCT07671911 · RECRUITING

Trial details

NCT number: NCT07671911
Sponsor: Trevi Therapeutics
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Idiopathic Pulmonary Fibrosis

Start date: 2026-06-29
Primary completion: 2028-06-01
Enrollment: 306

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.